Results 41 to 50 of about 34,135 (204)

Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance

Frontiers in Oncology, 2022
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently being used for treating breast cancer patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic diseases.
Mohammed Hafiz Uddin, Jun-Ying Zhou, Julio Pimentel, Steve M. Patrick, Steve M. Patrick, Steve M. Patrick, Seongho Kim, Seongho Kim, Malathy P. Shekhar, Malathy P. Shekhar, Malathy P. Shekhar, Gen Sheng Wu, Gen Sheng Wu, Gen Sheng Wu   +13 more
doaj   +1 more source

Triple negative breast cancer: new perspectives for targeted therapies [PDF]

, 2015
Breast cancer is a heterogeneous disease, encompassing a large number of entities showing different morphological features and having clinical behaviors.
Caruso, Davide, Frati, Luigi, Minozzi, Marina, Papa, Anselmo, Rossi, Luigi, Tomao, Federica, Tomao, Silverio, Vici, Patrizia, Zaccarelli, Eleonora   +8 more
core   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

Nature Communications
SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in ...
Chee Khoon Lee, Apriliana E. R. Kartikasari, Nirashaa T. Bound, Katherine E. Francis, Kristy Shield-Artin, Justin Bedo, Ksenija Nesic, Katrina Diamante, Rachel L. O’Connell, Mutsa Madondo, Momodou Cox, Claire Davies, Cyril Deceneux, Georgia Goodchild, Andrew Jarratt, Emily Cassar, Hina Amer, U. G. Imalki U. Kariyawasam, Yeh Chen Lee, Janine Lombard, Sally Baron-Hay, Yoland Antill, Catherine Shannon, Sudarshan Selva-Nayagam, Philip Beale, Danka Zebic, Sandy Simon, Anneliese Linaker, Michael A. Quinn, Anthony T. Papenfuss, Matthew J. Wakefield, Cassandra J. Vandenberg, Michael Friedlander, Clare L. Scott, Magdalena Plebanski   +34 more
doaj   +1 more source

Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature

BMC Pulmonary Medicine, 2023
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has demonstrated effectiveness in treating ovarian, breast, and other cancers, particularly those with specific molecular subtypes including, but not limited to, BRCA1/2 mutations ...
Hiroshi Ishimoto, Noriho Sakamoto, Takashi Kido, Mutsumi Ozasa, Shin Tsutsui, Mayako Mori, Daichi Setoguchi, Shinnosuke Takemoto, Yasushi Obase, Yuji Ishimatsu, Chiharu Tomonaga, Kanako Matsumoto, Sachiko Morisaki, Kiyonori Miura, Hiroshi Mukae   +14 more
doaj   +1 more source

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gábor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Journal for ImmunoTherapy of Cancer, 2018
Background Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a benefit of combining olaparib with
Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, James W. Hodge   +8 more
doaj   +1 more source

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis

BMC Cancer, 2023
Objective To analyze the incidence and risk of hypertension associated with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in cancer patients and provide reference for clinicians.
Xiu Chen, Qinglian Wen, Liqiu Kou, Xiaolu Xie, Jun Li, Yaling Li   +5 more
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

The combination of olaparib and camptothecin for effective radiosensitization

Radiation Oncology, 2012
Background Poly (ADP-ribose) polymerase-1 (PARP-1) is a key enzyme involved in the repair of radiation-induced single-strand DNA breaks. PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I
Miura Katsutoshi, Sakata Koh-ichi, Someya Masanori, Matsumoto Yoshihisa, Matsumoto Hideki, Takahashi Akihisa, Hareyama Masato   +6 more
doaj   +1 more source